Combined modality therapy for stage II and stage III pancreatic carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2920-2927

  Kamthan, Arvind G ^a   Morris, John C ^a   Dalton, Jack ^a   Mandeli, John P ^a   Chesser, Margaret R ^a   Leben, Dvora ^a   Cooperman, Avram ^a   Bruckner, Howard W ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; STREPTOZOCIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTINUOUS INFUSION; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OUTCOMES RESEARCH; PANCREAS CARCINOMA; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0030742115     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2920     Document Type: Article

References (53)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics. CA Cancer J Clin 46:5-27, 1996
2. Tsuchiya R, Noda T, Harada N, et al: Collective review of small carcinomas of the pancreas. Ann Surg 203:77-81, 1986
3. Crist DW, Sitzman JV, Cameron JL: Improved hospital morbidity, mortality and survival after the Whipple procedure. Ann Surg 206:358-365, 1987
4. Trede M, Schwall G, Saeger HD: Survival after pancreaticodoudenectomy. Ann Surg 211:447-458, 1990
5. Gudjonsson B: Carcinoma of the pancreas: Critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg 181:483-503, 1995
6. Tepper JE, Nardi GL, Suit HD: Carcinoma of the pancreas: Review of the MGH experience from 1963-1973: Analysis of surgical failure and implications for radiation therapy. Cancer 37:1519-1524, 1976
7. Griffin JF, Smalley SR, Jewell W, et al: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56-61, 1990
8. Nagai H, Kuroda A, Morioka Y: Lymphatic and local spread of T1 and T2 pancreatic cancer. Ann Surg 204:65-71, 1986
9. Willett CG, Lewandrowski K, Warshaw AL, et al: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 217:144-148, 1993
10. Hamlsam JB, Cavanaugh PJ, Struop SL: Radiation therapy in the treatment of unresectable adenocarcinoma of the pancreas. Cancer 32:1341-1345, 1973
11. Dobelbower RR Jr, Borgelt BB, Strubler KA, et al: Precision radiotherapy for cancer of the pancreas: Technique and results. Int J Radiat Oncol Biol Phys 6: 1127-1133, 1980
12. Whittington R, Dobelbower RR Jr, Mohiuddin M, et al: Radiotherapy of unresectable pancreatic carcinoma: A six year experience in 104 patients. Int J Radiat Oncol Biol Phys 7:1639-1644, 1981
13. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006-2010, 1987
14. Gastrointestinal Tumor Study Group: A multi-institutional comparative trial of radiation therapy alone and in combination with 5-FU for locally unresectable pancreatic cancer. Am Surg 189:205-211, 1979
15. The Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751-755, 1988
16. Howard JM, Jordan GL Jr: Cancer of the pancreas. Curr Probl Cancer 2:5-52, 1977
17. Warshaw AL, Femandez del Castillo C: Pancreatic carcinoma. N Engl J Med 326:455-465, 1992
18. Bruckner HW, Kalnicki S, Sung MW, et al: Combined modality (CM) therapy for stage II pancreatic cancer (PC) with simultaneous radiotherapy (RT), 5-fluorouracil (FU) infusion, streptozocin (STZ) and cisplatin (DDP) with leucovorin (LV) and FU maintenance. Proc Am Assoc Cancer Res 30:257, 1989 (abstr)
19. Kamthan A, Morris JC, Chesser MR: Combined modality therapy for effective local control in stage II and III pancreatic carcinoma. Proc Am Soc Clin Oncol 11:160, 1992 (abstr)
20. Beahrs OH, Henson DE, Hutter RV, et al (eds): Exocrine Pancreas. Manual for Staging of Cancer (ed 3). Philadelphia, PA, Lippincott, 1988, pp 109-114
21. Gunderson L, Willett CG: Pancreatic and hepatobiliary tract, in Perez CA, Brady LW (eds): Principles and Practices of Radiation Oncology. Philadelphia, PA, Lippincott, 1992, pp 985-999
22. Miller AB, Hoogstraten B, Staquat M: Reporting the results of cancer treatment. Cancer 47:207-214, 1981
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. BMDP Statistical Software: BMDP Statistical Software Manual. Berkeley, CA, University of California Press, 1985
25. Byfield JE, Chan PYM, Seagren S: Radiosensitization by 5-fluorouracil (5-FU): Molecular and clinical scheduling implications. Proc Am Assoc Cancer Res 18:74, 1974 (abstr)
26. Nakajima Y, Miyainoto T, Tanabes M, et al: Enhancement of mammalian cell killing by 5-fluorouracil in combination with x-rays. Cancer Res 135:185-206, 1979
27. Schein PS, O'Connell MJ, Blom J, et al: Clinical antitumor activity and toxicity of streptozocin (NSC-85998) Cancer 34:993-1000, 1974
28. Carter S, Comis RL: The integration of chemotherapy into a combined modality approach for cancer treatment VI. Pancreatic adenocarcinoma. Cancer Treat Rev 2:193-214, 1975
29. Wiggans RG, Wooley PV, MacDonald JS, et al: Phase II trial of streptozocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 41:387-391, 1978
30. Bukowski RM, Balcerzak SP, O'Bryan RM, et al: Randomized trial of streptozocin, mitomycin-C with or without streptozocin for advanced pancreatic cancer. A Southwest Oncology Group study. Cancer 52:1577-1582, 1983
31. Moertel CG, Rubin J, O'Connell MJ: A phase II study of combined 5fluorouracil, doxorubicin. and cisplatin in the treatment of upper gastrointestinal adenocarcinomas. J Clin Oncol 4:1053-10578, 1986
32. Wagener DJT, van Hoesel QGCM, Yap SH, et al: Phase II trial of 5-fluorouracil, Adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer. Cancer Chemother Pharmacol 25:131-314, 1989
33. Dougherty JB, Kelsen D, Kemeny N, et al: Advanced pancreatic cancer: A phase I-II trial of cisplatin, high-dose cytarabine, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68:965-969, 1991
34. Kelsen D, Hudis C, Niedzwiecki D, et al: Phase III comparison of streptozocin, mitomycin and 5-fluorouracil with cisplatin, cytosine arabinoside and caffeine in patients with advanced pancreatic carcinoma. Cancer 68:965-969, 1991
35. Forastiere AA, Orringer MB, Perez-Tamayo C, et al: Concurrent chemotherapy and radiation therapy followed by transhiatal esophagus. J Clin Oncol 8:119-127, 1990
36. Evans DB, Rich TA, Byrd DR, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1315-1319, 1992
37. Evans DB, Abbruzzese J, Lee J, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 13:226, 1994 (abstr)
38. Yeung RS, Weese JL, Hoffman JP, et al: Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study. Cancer 72:2124-2133, 1993
39. Dobelbower RR, Montemaggi P: Brachytherapy for pancreatic cancer: A review. Hepatogastroenterology 43:333-337, 1996
40. Roldan GE, Gunderson LL, Nagorney DM, et al: External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61:1110-1116, 1988
41. Kompki R, Wadlers S, Peters T, et al: High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for in-operable adenocarcinoma of the pancreas. Cancer 69:2807-2812, 1992
42. Wagener D, Rougier P, Wils J, et al: Combined chemoradiotherapy for locally advanced pancreatic cancer. Proc Am Soc Clin Oncol 11:166, 1992 (abstr)
43. Whittington R, Solin L, Mohiuddin M, et al: Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54:1991-1998, 1984
44. Gralla RJ: Preoperative and adjuvant chemotherapy in non-small cell lung cancer. Semm Oncol 15:8-12, 1988 (suppl 7)
45. Turk P, Wanebo HJ, Glicksman A, et al: Multimodality protocol for locally advanced carcinoma of the pancreas: A pilot program. Proc Am Soc Clin Oncol 11:187, 1992 (abstr)
46. Gattani A, Mandeli J, Bruckner HW: Tumor markers in pancreatic cancer. Cancer 78:57-62, 1996
47. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
48. Bruckner HW, Crown J, McKenna A, et al: Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res 48:5570-5572, 1988
49. Crown J, Cooper ES, Botet J, et al: Lack of efficacy of high dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9:1682-1686, 1991
50. DeCaprio JA, Mayer RJ, Gonin R, et al: Flurouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 9:2128-2133, 1991
51. Bruckner HW, Kalnicki S, Dalton J, et al: Survival following combined modality therapy for pancreatic cancer. J Clin Gastroenterol 16:199-203, 1993
52. Bruckner HW, Kalnicki S, Dalton J, et al: Combined modality therapy increasing local control of pancreatic cancer. Cancer Invest 11:241-246, 1993
53. Snady H, Bruckner H, Cooperman A, et al: Is pancreatoduodenectomy as initial treatment "the only chance for cure" for pancreatic adenocarcinoma? Proceedings of the American Gastroenterological Association and American Association for the Study of Liver Diseases, Washington, DC, May 11-14, 1997